ReviewIncreasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera
Introduction
IL-2 and IL-15 belong to a family of γc cytokines (IL-2, 4, 7, 9, 15, and 21) which are key regulators of lymphocyte homeostasis and function. They have the potential to promote lymphocyte proliferation and survival and thus overall enhance dominantly adaptive immune responses. IL-2 is an autocrine/paracrine soluble factor produced mainly by activated T cells, whereas IL-15 is produced by activated monocytes and dendritic cells (DCs) [1], [2], [3], and to a lesser extent by epithelial cells, stromal cells and fibroblasts [4], [5], [6].
Both cytokines share two receptor subunits, CD122 and CD132, β, and common γc chains, respectively. IL-2 exerts its pleiotropic activities through binding to either a dimeric receptor composed of CD122 and CD132 or a trimeric receptor composed of CD25, CD122 and CD132 [7]. The isolated CD25 binds IL-2 with low affinity (Ka ∼108 M−1) without transducing a signal [8], [9]. A dimer of CD122 and CD132 binds IL-2 with intermediate affinity (Ka ∼109 M−1) and is present on CD122high populations, namely memory CD8+ T cells (CD3+CD8+CD44highCD122high) and NK cells (CD3−NK1.1+DX5+) [10], [11]. A complex of CD25, CD122 and CD132 binds IL-2 with high affinity (Ka ∼1011 M−1) and is present on activated T cells and T regulatory cells (Treg; CD3+CD4+CD25+Foxp3+). CD25 is not expressed in naïve T cells but becomes transiently expressed at high levels upon T cell activation, allowing a selective IL-2 driven expansion of activated T cells. On the other hand, CD25 is constitutively expressed at high levels in Treg cells, enabling them to utilize very low background levels of IL-2.
In contrast to IL-2, IL-15 is membrane-associated cytokine acting through cell-cell contact. The dominant mechanism of IL-15 signaling in vivo is trans-presentation of IL-15 by IL-15Rα (CD215) to a heterodimeric CD122/CD132 receptor [12], [13]. Unlike CD25, IL-15Rα binds IL-15 with a very high affinity (Ka ∼1011 M−1) that is not further increased in the presence of the complete IL-15 receptor, i.e., IL-15 has ∼100-fold higher affinity to IL-15Rα than IL-2 to CD25 [14], [15]. IL-15Rα is not de facto a high-affinity receptor subunit, as it associates with IL-15 already in the endoplasmic reticulum and is necessary for its transport to the cell surface and subsequent delivery of the IL-15 signal [16]. IL-15Rα is expressed on T cells, NK cells, NKT cells, B cells, DCs, monocytes and macrophages, and in thymic and BM stromal cell lines [1], [2], [15], [17], [18]. However, IL-15Rα mRNA have also been detected in a number of non-lymphoid tissues such as liver, heart, spleen, lung, skeletal muscle and endothelial cells [15], [17], [19], which suggests that the IL-15/IL-15Rα signaling system operates in multiple tissues/organs throughout the organism.
IL-2 and IL-15 shares many functions in both the adaptive and innate immune system, because both cytokines signal through the same CD122/CD132 receptor heterodimer. Both cytokines promote proliferation and survival of T cells, induce the proliferation and differentiation of NK cells, as well as their cytolytic activity, and are able to facilitate production of immunoglobulins by B cells. However, IL-15 has in vivo functions distinct from IL-2, which is largely due to the unique manner in which it uses its IL-15Rα receptor. As such, IL-15 is important for the development and homeostasis of memory CD8+ T cells, iNKT cells and CD8αα intraepithelial lymphocytes [13].
Although IL-15 was initially described as a T-cell proliferative factor similar to IL-2, subsequent studies have shown that IL-2 and IL-15 can have quite opposite effects in vivo on T-lymphocyte growth and survival. IL-2 is involved in limiting T-cell numbers, as a continued exposure to IL-2 causes activation-induced cell death (AICD); additionally, IL-2 is critical to the development and function of Treg cells [20]. Mice deficient in IL-2 or CD25 develop a polyclonal lymphoproliferation with massive lymphadenopathy, splenomegaly and T-cell dependent autoimmunity [21], [22]. In contrast, IL-15 can inhibit IL-2-induced AICD [23]; IL-15-deficient (IL-15 KO) or IL-15Rα-deficient (IL-15Rα KO) mice exhibit lymphopenia rather than lymphoproliferation [24], [25]. IL-2 signaling in continuously dividing T cells leads to down-regulation of the common γc receptor and decreased bcl-2 expression, resulting in increased susceptibility to apoptosis; IL-15 signaling has no such effect [26]. IL-15 has been shown to be critical for the maintenance of memory CD8+ T cells [25], [27], [28], [29] and NK cells, since IL-15 KO and IL-15Rα KO mice do not have these populations [24], [30].
IL-2 has a potent stimulatory effect on T and NK cells and some other cells of the immune system. More than 20 years ago, IL-2 was approved by the FDA for treatment of metastatic renal cell carcinoma and malignant melanoma [31], [32]. However, although standard high-dose IL-2 therapy results in a modest clinical response rate of 14% [33], the treatment is limited by substantial toxicities [33], [34], vascular leak syndrome (VLS) being the most serious one [35], [36], [37]. Alternatively, low-dose IL-2 treatment has shown activity in renal cell cancer (response rates of 18–23%), without the toxicity of high dose IL-2 [38], [39]. Yet, IL-2 cancer therapy is of continued interest in part because about one-third of the clinical responses are complete, durable remissions.
So far, IL-2 immunotherapy has been shown to be beneficial in a variety of clinical trials [40], [41], [42], [43], [44]. For example, studies to identify antigen-nonspecific strategies for enhancing immune reconstitution in individuals with HIV infection include those using IL-2 [45]. Two recent studies that used IL-2 at much lower doses in different immune-mediated diseases now suggest that IL-2 may have a dominant role in immunosuppression, rather than in immune stimulation as originally thought. Koreth et al. [46] showed that IL-2 therapy reversed graft-versus-host disease in patients who had undergone allogeneic HSCT to treat lymphoma or leukemia. Similarly, Saadoun et al. [47] found that IL-2 treatment had clinical benefit in hepatitis C virus-related vasculitis. Increased numbers of Treg cells were observed after IL-2 treatment in both reports.
Treatment with IL-15 has many of the same effects as with IL-2 in mice, as it induces the proliferation of T cells, with a preference toward memory CD8+ T cells and NK cells. IL-15 could have advantage over IL-2 as it does not increase Treg levels as observed for IL-2. IL-15 can boost patients’ immune systems and restore immune responses against cancer and infectious diseases like HIV. Therefore, IL-15 has been studied since 2009 in patients with malignant melanoma and in patients with renal cell carcinoma [48]. Furthermore, IL-15 is currently being investigated in settings of immune deficiency, for the in vitro expansion of T and NK cells and as an adjuvant for vaccine strategies [49].
Section snippets
IL-2/anti-IL-2 mAb immunocomplexes
IL-2/anti-IL-2 mAb complexes, sometimes referred to as IL-2 immunocomplexes [50], are interesting and important for both basic immunology, as well as for the use of cytokines in immunotherapy. In 2006, the study of Boyman et al. [51] convincingly demonstrated that in vivo biological activity of IL-2 and possibly of some other cytokines could be dramatically increased via binding to its respective anti-cytokine antibody. Moreover, IL-2 immunocomplexes possess not only much higher, but also
IL-15 is naturally presented by IL-15Rα in trans
IL-15 operates in a different way than most other cytokines, which are secreted. Instead, the in vivo data shows that IL-15 exists as a biologically active membrane-bound IL-15/IL-15Rα complex, which possesses dual ligand/receptor qualities with the potential for inducing bi-directional signaling [80]. IL-15/IL-15Rα engages the βγc (CD122, CD132, respectively) receptor on nearby cells in a process termed trans-presentation (Fig. 3) [12]. This unusual process allows a more directed and
Conclusions
The in vivo biologic activity of IL-2 and IL-15 can be dramatically increased by complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera, respectively. IL-15/IL-15Rα-Fc complexes are more potent than IL-15, both in vitro and in vivo, while IL-2/anti-IL-2 mAb immunocomplexes are more potent than IL-2 only in vivo. However, IL-2/anti-IL-2 mAb immunocomplexes show selectivity in the stimulation of various IL-2-responding cell subsets, a feature dictated by the clone of anti-IL-2 mAb used. Both
Acknowledgements
This work was supported by grant 301/11/0325 and 13-12885S from GACR, by RVO: 61388971 and by the project “BIOCEV – Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University” (CZ.1.05/1.1.00/02.0109), from the European Regional Development Fund. Marek Kovar is listed as a co-inventor on the patent entitled “Methods for Improving Immune Function and Methods for Prevention or Treatment of Disease in a Mammalian subject”, which was filed on February 16, 2007 and now
Petra Votavova is a PhD student at the Laboratory of Tumor Immunology. She has recently defended her M.Sc. thesis on IL-2-poly(HPMA) conjugate and IL-15/IL-15Rα complexes. She specializes in IL-2, IL-15 and their respective complexes (with anti-IL-2 mAb or IL-15Rα-Fc, respectively) with regard to function and application, not limited to experimental tumor models. She is the co-author of several papers in major immunological journals.
References (111)
- et al.
Biology of the interleukin-2 receptor
Adv Immunol
(1998) - et al.
Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15
Immunity
(1998) - et al.
IL-15Rα recycles and presents IL-15 in trans to neighboring cells
Immunity
(2002) - et al.
Regulating the immune system via IL-15 transpresentation
Cytokine
(2012) - et al.
Intracellular interaction of interleukin-15 with its receptor α during production leads to mutual stabilization and increased bioactivity
J Biol Chem
(2008) - et al.
Functional characterization of the human interleukin-15 receptor α chain and close linkage of IL15RA and IL2RA genes
J Biol Chem
(1995) - et al.
Transregulation of memory CD8 T-cell proliferation by IL-15Rα+ bone marrow-derived cells
Blood
(2004) - et al.
Interleukin-15 promotes angiogenesis in vivo
Biochem Biophys Res Commun
(1997) - et al.
CD4+ regulatory T cells in autoimmunity and allergy
Curr Opin Immunol
(2002) - et al.
Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment
Immunity
(1995)
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene
Cell
IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation
Immunity
Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial
Ann Oncol
rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo
Tuber Lung Dis
Modeling interleukin-2-based immunotherapy in AIDS pathogenesis
J Theor Biol
IL-15 in the life and death of lymphocytes: immunotherapeutic implications
Trends Mol Med
Rapid generation of a functional NK-cell compartment
Blood
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction
Immunity
Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation
Blood
Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis
Immunol Today
IL-15 is elevated in serum patients with type 1 diabetes mellitus
Diabetes Res Clin Pract
Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum
Blood
Natural splicing of exon 2 of human interleukin-15 receptor α-chain mRNA results in a shortened form with a distinct pattern of expression
J Biol Chem
Identification of an interleukin-15α receptor-binding site on human interleukin-15
J Biol Chem
The structure of the IL-15α-receptor and its implication for ligand binding
J Biol Chem
The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens
Annu Rev Immunol
IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation
J Immunol
Induction and regulation of IL-15 expression in murine macrophages
J Immunol
Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis?
J Immunol
Dermal fibroblasts sustain proliferation of activated T cells via membrane-bound interleukin-15 upon long-term stimulation with tumor necrosis factor-α
J Invest Dermatol
CD40 ligation enhances IL-15 production by tubular epithelial cells
J Am Soc Nephrol
Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor
Proc Natl Acad Sci U S A
The interleukin 2 receptor. Functional consequences of its bimolecular structure
J Exp Med
The structure of interleukin-2 complexed with its alpha receptor
Science
IL-2 and IL-15 receptor α-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells
Proc Natl Acad Sci U S A
Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor
EMBO J
IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice
Proc Natl Acad Sci U S A
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice
J Exp Med
T cell-independent interleukin 15rα signals are required for bystander proliferation
J Exp Med
IL-15 and IL-2: a matter of life and death for T cells in vivo
Nat Med
Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8T cells
J Immunol
Interleukin 15 is required for proliferative renewal of virus-specific memory CD8T cells
J Exp Med
Cytokine requirements for acute and basal homeostatic proliferation of naive and memory CD8+ T cells
J Exp Med
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma. A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006
Cancer
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines
Clin Can Res
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
J Clin Oncol
Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989–1997
Cancer J Sci Am
Application of IL-2 and other cytokines in renal cancer
Expert Opin Biol Ther
Mechanisms of interleukin-2-induced hepatic toxicity
Cancer Res
NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome
J Immunol
Cited by (28)
Cytokine Receptors and Their Ligands
2022, Encyclopedia of Cell Biology: Volume 1-6, Second EditionControl of human toxoplasmosis
2021, International Journal for ParasitologyNatural Killer Cells Degenerate Intact Sensory Afferents following Nerve Injury
2019, CellCitation Excerpt :In contrast, NK depleted mice showed an early and persistent sensitivity to pinprick stimulation (Figure S5I, DTx) and displayed an anatomically broad pattern of responses to stimulation across the hind paw prior to full recovery (Figure S5J, DTx), indicative of sporadic intact innervation throughout the paw. To replicate the stimulation of NK cells by IL-2 in vitro, we treated mice systemically with an IL-2/anti-IL-2 monoclonal (S4B6) antibody complex (Votavova et al., 2014), leading to enrichment of NKp46+DX5+ and CD3+CD8+ lymphocyte populations (Boyman et al., 2006) (Figure 5A). To determine whether NK cells could selectively degenerate partially injured axons, we delivered a reproducible partial sciatic nerve crush (see STAR Methods).
The common γ-chain cytokine IL-7 promotes immunopathogenesis during fungal asthma
2018, Mucosal ImmunologyInterleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells
2018, ImmunityCitation Excerpt :Furthermore, we found that NK cells were the predominant population of IL-10-producing cells induced by IL-15C treatment, that both NK cells and IL-10 were required for IL-15C-mediated protection against ECM, and that the capacity of IL-15C-treated NK cells to transfer protection depended on their ability to make IL-10. Our finding that IL-2C treatment does not protect against ECM and also fails to induce IL-10 production by NK cells led us to reveal the key role of NK cell-produced IL-10 in control of the disease: the different effects of in vivo IL-2C and IL-15C treatments occurred despite the fact that the cytokine complexes are believed to signal through the same receptor chains and both lead to expansion of NK cells and memory phenotype CD8+ T cells (Boyman et al., 2006; Votavova et al., 2014). In vitro studies show that mouse NK cells stimulated to proliferate (by MCMV infection or culture with high doses of IL-2) make IL-10 in response to IL-12 or IL-21 (Tarrio et al., 2014), and our studies suggest that either IL-2 or IL-15 can cooperate with IL-21 and IL-12 to induce human NK cells to make IL-10.
Petra Votavova is a PhD student at the Laboratory of Tumor Immunology. She has recently defended her M.Sc. thesis on IL-2-poly(HPMA) conjugate and IL-15/IL-15Rα complexes. She specializes in IL-2, IL-15 and their respective complexes (with anti-IL-2 mAb or IL-15Rα-Fc, respectively) with regard to function and application, not limited to experimental tumor models. She is the co-author of several papers in major immunological journals.
Jakub Tomala is a junior research fellow and a postdoc at the Laboratory of Tumor Immunology. He has recently defended his PhD thesis on IL-2 immunocomplexes. His main research focus is on investigating the potential of IL-2 immunocomplexes in cancer immunotherapy. He is also well established in the field of HPMA copolymer-based drugs. He is the author of several papers and co-author of others in major immunological and cancer journals.
Marek Kovar is a senior research fellow and a Head of the Laboratory of Tumor Immunology. His research focuses on T cells immunology, IL-2 and immunocomplexes of IL-2 and anti-IL-2 mAb. He is also an expert in the field of anti-cancer therapeutics based on HPMA copolymer-bound cytostatic drugs. He has published many distinguished papers on the topics of IL-2 immunocomplexes and HPMA copolymer-based drugs.